CC BY-NC 4.0 · Arch Plast Surg 2021; 48(06): 685-690
DOI: 10.5999/aps.2020.02285
Extremity/Lymphedema
Original Article

Excisional lipectomy versus liposuction in HIV-associated lipodystrophy

Department of Plastic Surgery, University of California Irvine, Orange, CA, USA
,
Department of Plastic Surgery, University of California Irvine, Orange, CA, USA
,
School of Medicine, University of California Irvine, Orange, CA, USA
,
Department of Plastic Surgery, University of California Irvine, Orange, CA, USA
› Author Affiliations

Background Human immunodeficiency virus (HIV)-associated lipodystrophy is a known consequence of long-term highly active antiretroviral therapy (HAART). However, a significant number of patients on HAART therapy were left with the stigmata of complications, including fat redistribution. Few studies have described the successful removal of focal areas of lipohypertrophy with successful outcomes. This manuscript reviews the outcomes of excisional lipectomy versus liposuction for HIV-associated cervicodorsal lipodystrophy.

Methods We performed a 15-year retrospective review of HIV-positive patients with lipodystrophy. Patients were identified by query of secure operative logs. Data collected included demographics, medications, comorbidities, duration of HIV, surgical intervention type, pertinent laboratory values, and the amount of tissue removed.

Results Nine male patients with HIV-associated lipodystrophy underwent a total of 17 procedures. Of the patients who underwent liposuction initially (n=5), 60% (n=3) experienced a recurrence. There were a total of three cases of primary liposuction followed by excisional lipectomy. One hundred percent of these cases were noted to have a recurrence postoperatively, and there was one case of seroma formation. Of the subjects who underwent excisional lipectomy (n=4), there were no documented recurrences; however, one patient’s postoperative course was complicated by seroma formation.

Conclusions HIV-associated lipodystrophy is a disfiguring complication of HAART therapy with significant morbidity. Given the limitations of liposuction alone as the primary intervention, excisional lipectomy is recommended as the primary treatment. Liposuction may be used for better contouring and for subsequent procedures. While there is a slightly higher risk for complications, adjunctive techniques such as quilting sutures and placement of drains may be used in conjunction with excisional lipectomy.



Publication History

Received: 16 November 2020

Accepted: 06 September 2021

Article published online:
22 May 2022

© 2021. The Korean Society of Plastic and Reconstructive Surgeons. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonCommercial License, permitting unrestricted noncommercial use, distribution, and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes. (https://creativecommons.org/licenses/by-nc/4.0/)

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • REFERENCES

  • 1 Finkelstein JL, Gala P, Rochford R. et al. HIV/AIDS and lipodystrophy: implications for clinical management in resource-limited settings. J Int AIDS Soc 2015; 18: 19033
  • 2 Raggio GA, Looby SE, Robbins GK. et al. Psychosocial correlates of body image and lipodystrophy in women aging with HIV. J Assoc Nurses AIDS Care 2020; 31: 157-66
  • 3 Mallon PW, Cooper DA, Carr A. HIV-associated lipodystrophy. HIV Med 2001; 2: 166-73
  • 4 Carr A, Samaras K, Burton S. et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-8
  • 5 Miller KD, Jones E, Yanovski JA. et al. Visceral abdominalfat accumulation associated with use of indinavir. Lancet 1998; 351: 871-5
  • 6 Mallon PW, Wand H, Law M. et al. Buffalo hump seen in HIV-associated lipodystrophy is associated with hyperinsulinemia but not dyslipidemia. J Acquir Immune Defic Syndr 2005; 38: 156-62
  • 7 Boubaker K, Flepp M, Sudre P. et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis 2001; 33: 1931-7
  • 8 Martinez E, Mocroft A, Garcia-Viejo MA. et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001; 357: 592-8
  • 9 Global Statistics [Internet]. Washington, D.C.: U.S. Department of Health & Human Services; c2019 [cited 2020 Apr 28]. Available from: https://www.hiv.gov/hiv-basics/overview/data-and-trends/global-statistics
  • 10 Ammassari A, Antinori A, Cozzi-Lepri A. et al. Relationship between HAART adherence and adipose tissue alterations. J Acquir Immune Defic Syndr 2002; 31 Suppl 3: S140-4
  • 11 Leung VL, Glesby MJ. Pathogenesis and treatment of HIV lipohypertrophy. Curr Opin Infect Dis 2011; 24: 43-9
  • 12 Tsuda LC, da Silva MM, Machado AA. et al. Body changes: antiretroviral therapy and lipo-dystrophy syndrome in people living with HIV/AIDS. Rev Lat Am Enfermagem 2012; 20: 847-53
  • 13 Singhania R, Kotler DP. Lipodystrophy in HIV patients: its challenges and management approaches. HIV AIDS (Auckl) 2011; 3: 135-43
  • 14 Guallar JP, Gallego-Escuredo JM, Domingo JC. et al. Differential gene expression indicates that ‘buffalo hump’ is a distinct adipose tissue disturbance in HIV-1-associated lipodystrophy. AIDS 2008; 22: 575-84
  • 15 Wohl DA, McComsey G, Tebas P. et al. Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis 2006; 43: 645-53
  • 16 Hultman CS, McPhail LE, Donaldson JH. et al. Surgical management of HIV-associated lipodystrophy: role of ultrasonic-assisted liposuction and suction-assisted lipectomy in the treatment of lipohypertrophy. Ann Plast Surg 2007; 58: 255-63
  • 17 Fiorenza CG, Chou SH, Mantzoros CS. Lipodystrophy: pathophysiology and advances in treatment. Nat Rev Endocrinol 2011; 7: 137-50
  • 18 Piliero PJ, Hubbard M, King J. et al. Use of ultrasonography-assisted liposuction for the treatment of human immunodeficiency virus-associated enlargement of the dorsocervical fat pad. Clin Infect Dis 2003; 37: 1374-7
  • 19 Magann EF, Chauhan SP, Rodts-Palenik S. et al. Subcutaneous stitch closure versus subcutaneous drain to prevent wound disruption after cesarean delivery: a randomized clinical trial. Am J Obstet Gynecol 2002; 186: 1119-23
  • 20 Ion L, Raveendran SS. Open neck lipectomy for patients with HIV-related cervical lipohypertrophy. Aesthetic Plast Surg 2011; 35: 953-9
  • 21 Tsui E, Bogdasarian R, Blomain E. The successful use of lipectomy in the management of airway obstruction in a woman with HIV-associated lipodystrophy. BMJ Case Rep 2015; 2015: bcr2014208053
  • 22 Fuller J. A 39-year-old man with HIV-associated lipodystrophy. JAMA 2008; 300: 1056-66
  • 23 Sharma D, Bitterly TJ. Buffalo hump in HIV patients: surgical management with liposuction. J Plast Reconstr Aesthet Surg 2009; 62: 946-9
  • 24 Warren AG, Borud LJ. Excisional lipectomy for HIV-associated cervicodorsal lipodystrophy. Aesthet Surg J 2008; 28: 147-52
  • 25 Roostaeian J, Jarrahy R, Kaufman MR. et al. Power-assisted liposuction treatment of cervicodorsal fat pad in human immunodeficiency virus-associated lipodystrophy. Plast Reconstr Surg 2008; 121: 135e-136e
  • 26 Nelson L, Stewart KJ. Experience in the treatment of HIV-associated lipodystrophy. J Plast Reconstr Aesthet Surg 2008; 61: 366-71
  • 27 Gold DR, Annino Jr DJ. HIV-associated cervicodorsal lipodystrophy: etiology and manage-ment. Laryngoscope 2005; 115: 791-5
  • 28 Gervasoni C, Ridolfo AL, Vaccarezza M. et al. Long-term efficacy of the surgical treatment of buffalo hump in patients continuing antiretroviral therapy. AIDS 2004; 18: 574-6
  • 29 Wolfort FG, Cetrulo Jr CL, Nevarre DR. Suction-assisted lipectomy for lipodystrophy syndromes attributed to HIVprotease inhibitor use. Plast Reconstr Surg 1999; 104: 1814-22
  • 30 Ponce-de-Leon S, Iglesias M, Ceballos J. et al. Liposuction for protease-inhibitor-associated lipodystrophy. Lancet 1999; 353: 1244